What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.

ABSTRACT:

Background

The safety profile of COVID-19 vaccines in immunocompromised patients has not been comprehensively evaluated.

Aim

To measure the frequency of patient-reported adverse drug reactions (ADRs) related to the first/second/booster dose of COVID-19 vaccine in immunocompromised subject versus matched cohort. As a secondary objective, the time course, evaluated as time to onset (TTO) and time to recovery (TTR), of COVID-19 vaccine-related ADRs was explored.

Methods

A prospective cohort study, based on electronic questionnaires filled by vaccinees from 11 European countries in the period February 2021 to February 2023 was conducted. All immunocompromised vaccinees who provided informed consent and registered to the project's web-app within 48 h after first/booster va

SUBMITTER: Bellitto C 

PROVIDER: S-EPMC11399172 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature